Developing dynamic combinatorial chemistry as a platform for drug discovery
dc.contributor.advisor
Campopiano, Dominic
en
dc.contributor.advisor
Hulme, Alison
en
dc.contributor.author
Ekström, Alexander Gösta
en
dc.date.accessioned
2018-06-05T11:00:23Z
dc.date.available
2018-06-05T11:00:23Z
dc.date.issued
2018-07-09
dc.description.abstract
Dynamic combinatorial chemistry (DCC) is a powerful tool to identify new ligands for
biological targets. In the technique, library synthesis and hit identification are neatly
combined into a single step. A labile functionality between fragments allows the
biological target to self-select binders from a dynamic combinatorial library (DCL) of
interconverting building blocks. The scope of suitable reversible reactions that
proceed under thermodynamic control in physiological conditions has been gradually
expanded over the last decades, however DCC has thus far failed to gain traction as
a technique appropriate for drug discovery in the pharmaceutical industry. The
constraints placed on library size by validated analytical techniques, and the effort-intensive
reality of this academically elegant concept have not allowed DCC to
develop into a broad-platform technique to compete with the high-throughput
screening campaigns favoured by medicinal chemists. This thesis seeks to develop
DCL analysis techniques, in an effort to increase the library size and accelerate the
analysis of DCC experiments.
Using a 19F-labelled core scaffold, we constructed a DCL that could be monitored non-invasively
by 19F NMR. Building on NMR techniques developed by fragment screening
and non-biological DCC campaigns, the method was developed to circumvent the
undesired equilibrium-perturbing side effects arising from sample-consuming
analytical methods. The N-acylhydrazone (NAH) DCL equilibrated rapidly at pH 6.2
using 4-amino-L-phenylalanine (4-APA) as a novel, physiologically benign,
nucleophilic catalyst. The DCL was designed to target b-ketoacyl-ACP synthase III
(FabH), an essential bacterial enzyme and antibiotic target. From the 5-membered
DCL, a single combination was identified as a privileged structure by our 19F NMR
method. The result correlated well with an in vitro assay, validating 19F NMR as a tool
for DCL screening.
During the 19F NMR study we identified an established antimicrobial compound, 4,5-
dichloro-1,2-dithiole-3-one (HR45), to have potential as a core scaffold from which to
develop future DCLs targeting FabH. Despite the potentially tractable chemistry of
HR45 for DCC, lack of knowledge around the inhibitory mechanism of the compound
prevented us from proceeding. Thus, we used mass spectrometry, NMR and
molecular modelling to show that HR45 acts by forming a covalent adduct with S.
aureus FabH. The 5-chloro substituent directs attack from the nucleophilic thiol side
chain of the essential active site cysteine-112 residue via a Michael-type addition
elimination mechanism. Although interesting, this mechanism disfavoured the use of
HR45 as a core scaffold for NAH exchange in a DCC campaign.
Electrospray ionisation mass spectrometry (ESI-MS) is a powerful technique that
allows for larger DCLs by eliminating the size-limitations imposed by the need for
spectral or chromatographic resolution of DCL members. We developed a 4-APAcatalysed
NAH library targeting the pyridoxal 5’-phosphate (PLP) dependent enzyme
7,8-diaminopelargonic acid synthase (BioA), an essential enzyme in the biotin
biosynthesis pathway. We exploited the aldehyde moiety of PLP to form an NAH DCL
with a panel of hydrazides, and used the BioA isozymes from M. tuberculosis (Mtb)
and E. coli to template the library. A combination of buffer exchange and denaturing
ESI-MS allowed us to conduct a DCC experiment with a 29-member DCL. Hits from
the DCC experiment correlated well with differential scanning fluorimetry (DSF)
results. Of these hits, 5 compounds were selected for further study. In vivo activity
was displayed by 2 compounds against E. coli and the ESKAPE pathogen A. baumannii.
The identification of compounds with antibacterial activity from a DCL further
validates ESI-MS as a platform technology for drug discovery.
en
dc.identifier.uri
http://hdl.handle.net/1842/31073
dc.language.iso
en
dc.publisher
The University of Edinburgh
en
dc.relation.hasversion
Ekström, A. G.; Kelly, V.; Marles-Wright, J.; Cockroft, S. L. and Campopiano, D. J., Org. Biomol. Chem., 2017, 15 (30), 6310-6313
en
dc.subject
dynamic combinatorial chemistry
en
dc.subject
DCC
en
dc.subject
enzymes
en
dc.subject
DCL analysis techniques
en
dc.subject
ESI-MS
en
dc.subject
platform technology
en
dc.subject
drug discovery
en
dc.title
Developing dynamic combinatorial chemistry as a platform for drug discovery
en
dc.type
Thesis or Dissertation
en
dc.type.qualificationlevel
Doctoral
en
dc.type.qualificationname
PhD Doctor of Philosophy
en
Files
Original bundle
1 - 1 of 1
- Name:
- Ekström2018.pdf
- Size:
- 17.56 MB
- Format:
- Adobe Portable Document Format
This item appears in the following Collection(s)

